Open Targets: 10 years of partnership in target discovery

Hulcoop, David G.; Trynka, Gosia; McDonagh, Ellen M.

doi:10.1038/d41573-024-00204-2

COMMENT
17 December 2024

Open Targets: 10 years of partnership in target discovery

The Open Targets consortium was founded in 2014 to translate insights from genetics and functional genomics into identifying and prioritizing therapeutic targets. We highlight key achievements and insights stemming from this partnership of academic and industry scientists.

By

David G. Hulcoop⁰,
Gosia Trynka¹ &
Ellen M. McDonagh²

David G. Hulcoop
1. Open Targets, Wellcome Genome Campus, Hinxton, Cambridgeshire, UK; European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire, UK; Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridgeshire, UK.
View author publications

Search author on: PubMed Google Scholar
Gosia Trynka
1. Open Targets, Wellcome Genome Campus, Hinxton, Cambridgeshire, UK; Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridgeshire, UK.
View author publications

Search author on: PubMed Google Scholar
Ellen M. McDonagh
1. Open Targets, Wellcome Genome Campus, Hinxton, Cambridgeshire, UK; European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire, UK; Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridgeshire, UK.
View author publications

Search author on: PubMed Google Scholar

Access through your institution

Buy or subscribe

Introduction

Access options

Access through your institution

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 24, 153-154 (2025)

doi: https://doi.org/10.1038/d41573-024-00204-2

References

Nelson, M. et al. The support of human genetic evidence for approved drug indications. Nat. Genet. 47, 856–860 (2015).
Article PubMed Google Scholar
Behan, F. M. et al. Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens. Nature 568, 511–516 (2019).
Article PubMed Google Scholar
Gribben, C. et al. Acquisition of epithelial plasticity in human chronic liver disease. Nature 630, 166–173 (2024).
Article PubMed Google Scholar
Buniello, A. et al. Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Open Nucleic Acids Res. https://doi.org/10.1093/nar/gkae1128 (2024).
McDonagh, E. M. et al. Human genetics and genomics for drug target identification and prioritization: Open Targets’ perspective. Annu. Rev. Biomed. Data Sci. 7, 59–81 (2024).
Article PubMed Google Scholar

Download references

Reprints and permissions

Competing Interests

G.T. consults for BMS, Genentech, GSK and Relation Tx, and serves on the scientific advisory board of Variant Bio.

Jobs

Institute of Nanotechnology And Intelligence Global Recruitment for Outstanding Young Scientists

Exceptional young scholars worldwide with strong research achievements in relevant fields

Guangzhou, Guangdong (CN)

Institute of Nanotechnology and Intelligence (inAI), Jinan University, China.
Principal Investigator Positions at The Institute for Molecular and Cellular Therapeutics

Assistant Investigator, Associate Investigator,Senior Investigator.

Beijing (CN)

The Chinese Institutes for Medical Research (CIMR), Beijing
Postdoc openings in HIV immunology at Dr. Liang Shan Lab, SMART

Join Shan Lab to study HIV-1 immunity—a good chance to work on research toward an HIV cure.

Shenzhen, Guangdong (CN)

Shenzhen Medical Academy of Research and Translation
Postdoctoral Research Associate - Omenn-Darling Postdoctoral Fellowship (ODF)

The Omenn-Darling Bioengineering Institute invites applications for the Gilbert S. Omenn, MD. '61 & Martha A. Darling *70 Postdoc Fellowship Program.

Princeton, New Jersey

Princeton University - Omenn-Darling Bioengineering Institute
Postdoctoral Research Associate - Omenn-Darling Bioengineering Institute Innovators Fellow (ODBI2)

The Omenn-Darling Bioengineering Institute at Princeton University invites applications for the ODBI2 Postdoctoral program.

Princeton, New Jersey

Princeton University - Omenn-Darling Bioengineering Institute

[1] Nelson, M. et al. The support of human genetic evidence for approved drug indications. Nat. Genet. 47, 856–860 (2015).
Article PubMed Google Scholar

[2] Behan, F. M. et al. Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens. Nature 568, 511–516 (2019).
Article PubMed Google Scholar

[3] Gribben, C. et al. Acquisition of epithelial plasticity in human chronic liver disease. Nature 630, 166–173 (2024).
Article PubMed Google Scholar

[4] Buniello, A. et al. Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Open Nucleic Acids Res. https://doi.org/10.1093/nar/gkae1128 (2024).

[5] McDonagh, E. M. et al. Human genetics and genomics for drug target identification and prioritization: Open Targets’ perspective. Annu. Rev. Biomed. Data Sci. 7, 59–81 (2024).
Article PubMed Google Scholar

Access options

References

Competing Interests

Jobs

Institute of Nanotechnology And Intelligence Global Recruitment for Outstanding Young Scientists

Principal Investigator Positions at The Institute for Molecular and Cellular Therapeutics

Postdoc openings in HIV immunology at Dr. Liang Shan Lab, SMART

Postdoctoral Research Associate - Omenn-Darling Postdoctoral Fellowship (ODF)

Postdoctoral Research Associate - Omenn-Darling Bioengineering Institute Innovators Fellow (ODBI2)

Search

Quick links